Nicaragua Sessions: Contest for Young Interventionists

Sponsored by Abbott Vascular LATAM

33rd SOLACI Regional Sessions – 12° Central America and the Caribbean Regional Meeting

September 29th and 30th, 2017.

Managua, Nicaragua.


Case Submission: “Fostering Hemodynamics among Young Cardiologists”.

 

It is with great pleasure that we hereby invite all young Latin American cardiologists specializing in hemodynamics to submit relevant clinical cases to the next SOLACI Sessions, Managua, Nicaragaua, to be held on September 29th and 30th, 2017.

 

Participants will be competing for the “best case” prize, which consists of complete coverage to attend to a future SOLACI Session, including air fare, accommodation and registration. Winner will have the chance to choose amongst a SOLACI Session, to be held next year.

 

Submitted cases must be of educational value and must pertain to the field of interventional cardiology.

 

All cases will be initially evaluated by the appointed committee and shortlisted to the best 8, which shall be presented orally during our sessions. During these presentations, a second complementary evaluation will decide on the winner.

 

New Case submission deadline: September 22nd, 2017.

 

 Submission Criteria and Specifications:

 

  • Case submission is meant for young Latin American interventional cardiologists and topics include: adult peripheral vascular and structural heart interventional cardiology.

 

  • In each case only one interventionist can sign. Being a fellow cardiologist or interventionist is not required.

 

  • Attach a letter of recommendation from the Chief of the Hemodynamic Service you belong to.

 

  • Send a Word file with your case description, no longer than 300 words, font size 11.

 

  • Send a complementary Power Point file with your case presentation. Even though you may use videos for your oral presentation during our sessions (up to 5), this initial file may only include up to 5 pictures only.

 

  • One cardiologist may present more than one case. If such were the case, they should be sent separately.

 

  • Cases shall be submitted via this 

 

Dr. Jorge Mayol

SOLACI Session Director

Dr. Mario Araya

SOLACI Sessions Vice Director

Dr. Daniel Meneses

Organizing Committee of SOLACI Sessions Nicaragua 2017

Dr. Rogelio Jirón

Scientific Committee of SOLACI Sessions Nicaragua 2017

Dres. Gustavo Vignolo

Medical Images Contest Coordinator

Dres. Erick Hornez y Marcelo Halac

Solidary Program Coordinators 

 

More articles by this author

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...